0.17
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Market Closed
| Volume | 283,797 |
|
|||||
| News | - | ||||||
| Day High | 0.17 | Low High |
|||||
| Day Low | 0.165 | ||||||
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Canna Trader Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Oncotelic Therapeutics Inc (QB) | OTLC | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 0.17 | 16:23:29 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.17 | 0.165 | 0.17 | 0.17 | 0.17 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 31 | 283,797 | $ 0.16873 | $ 47,885 | - | 0.0805 - 0.36 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:04:20 | average | 95,000 | $ 0.16666 | USD |
Period:
Draw Mode:
Oncotelic Therapeutics Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 62.74M | 369.08M | 170.97M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 22.31k | $ - | - | - | - |
Oncotelic Therapeutics (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OTLC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.1645 | 0.18 | 0.1556 | 0.174273 | 300,308 | 0.0055 | 3.34% |
| 1 Month | 0.155 | 0.195 | 0.14 | 0.1706199 | 196,211 | 0.015 | 9.68% |
| 3 Months | 0.1159 | 0.199 | 0.0805 | 0.1499567 | 255,374 | 0.0541 | 46.68% |
| 6 Months | 0.18 | 0.199 | 0.0805 | 0.1389928 | 226,915 | -0.01 | -5.56% |
| 1 Year | 0.24 | 0.36 | 0.0805 | 0.1805689 | 219,257 | -0.07 | -29.17% |
| 3 Years | 0.24 | 0.36 | 0.0805 | 0.1805689 | 219,257 | -0.07 | -29.17% |
| 5 Years | 0.24 | 0.36 | 0.0805 | 0.1805689 | 219,257 | -0.07 | -29.17% |
Oncotelic Therapeutics (QB) Description
| Mateon has three major business segments: 1) PointR- developer of vision grid/cluster computing/AI to support drug development. 2) Mateon/Oxigene- developer of Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma in 2020 and OXi4503 rare pediatric designation for pediatric ALL. 3) Oncotelic- developer of OT-101 - an antisense against TGF-beta- for the treatment of cancers. OT-101 completed phase 2 with good safety and efficacy against pancreatic cancer, glioblastoma, and melanoma. OT-101 also been granted rare pediatric designation against pediatric DIPG in 2019. OT-101 is also being deployed against COVID-19. OT-101 is in phase 2 clinical trial against COVID. We are also developing Artemisinin in phase 4 clinical trial against COVID. It is approved by India for symptoms frequently observed in COVID. It is being launch by end of 2020. Global launch will be soon after. |